AbbVie Stock News

AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV's valuation remains attractive; a 14.4x FY 2027 multiple is compelling if earnings materialize, with technicals supporting a bullish breakout. Risks include Humira revenue erosion, pipeline uncertainty, and debt burden, but ABBV's clean loss-of-exclusivity profil...

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income.

Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.

Consumer staples and healthcare can be durable industries to invest in. Costco is highly profitable and relies on its proven membership model.

AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected.

Amazon and Alphabet are key leaders in the AI race on top of their flagship businesses. Walmart benefits from consistent non-discretionary spending like groceries.

When inflation drops, as we saw in the November consumer price index report, the Federal Reserve typically continues to cut interest rates, making fixed-income alternatives less attractive.